Transparency Looms Large In US FDA’s Next-Pandemic Legislative Agenda
Executive Summary
Agency’s proposals for pandemic preparedness reauthorization would build on CARES Act provisions to gain greater visibility into global pharmaceutical supply chains, while also seeking deeper understanding of manufacturing quality management activities. Also included in FY 2024 budget request: long-sought drug destruction and drug recall authorities.
You may also be interested in...
US FDA Should Reload Field Force To Target OTC Adulteration, Former Chief Counsel Hutt Says
Habitually noncompliant companies are laughing at FDA, Peter Barton Hutt says.
Supply Chain Confidentiality Doesn’t Stand 'Sunshine Test', Califf Says
US FDA commissioner takes aim at supplier confidentiality in remarks at ISPE annual meeting. But while greater transparency would help avert individual shortages, better economics for generic drugs are needed to solve the problem, he said.
Supply Chain Confidentiality Doesn’t Stand “Sunshine Test,” Califf Says In Comments On Drug Shortages
US FDA commissioner takes aim at supplier confidentiality in remarks at ISPE annual meeting. But while greater transparency would help avert individual shortages, better economics for generic drugs are needed to solve the problem, he said.